Zolinza

Indications and uses
ZOLINZA, a histone deacetylase (HDAC) inhibitor, is suitable for patients with cutaneous T-cell lymphoma (CTCL) who have progressed, persistent or relapsed diseases, and can be treated by two kinds of systemic therapy or post-cutaneous manifestations.

usage
(1)1400 mg oral once a day with food.
(2) If the patient can’t tolerate the treatment, the dose may be reduced to 300 mg with food once a day. If necessary, the dose may be further reduced to 300 mg once a day, with food for 5 consecutive days a week.

Dosage forms and specifications
Capsule: 100 mg

contraindication
Severe liver injury

Warnings and precautions
(1) Pulmonary embolism and deep vein thrombosis have been reported. Monitor related signs and symptoms of patients.
(2) Dose-related thrombocytopenia and anemia have occurred and may need to be adjusted or terminated.
(3) Gastrointestinal dysfunction (such as nausea, vomiting and diarrhea) has been reported. Patients may need antiemetics, antidiarrheal drugs and liquid and electrolyte replacement (to prevent dehydration).
(4) Patients with mild and moderate liver damage should be treated with caution.
(5) Hyperglycemia has been observed. Adjust the diet and/or may need to treat increased glucose.
(6) Monitor electrolytes regularly at baseline and during treatment.
(7) Monitor blood cell count and chemical tests, including electrolytes, glucose and serum creatinine, every 2 weeks during the first 2 months of treatment and every month thereafter.
(8) It has been reported that ZOLINZA combined with other HDAC inhibitors (for example, [valproic acid]) causes severe thrombocytopenia and gastrointestinal bleeding. Monitor platelet count.
(9) Fetal harm may occur when pregnant women give drugs. Women should be warned about the potential harm to the fetus.

adverse effect
The most common adverse reactions (incidence ≥20%) are diarrhea, fatigue, nausea, thrombocytopenia, loss of appetite and taste disorder.